586 related articles for article (PubMed ID: 19884534)
1. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Senzer NN; Kaufman HL; Amatruda T; Nemunaitis M; Reid T; Daniels G; Gonzalez R; Glaspy J; Whitman E; Harrington K; Goldsweig H; Marshall T; Love C; Coffin R; Nemunaitis JJ
J Clin Oncol; 2009 Dec; 27(34):5763-71. PubMed ID: 19884534
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
[TBL] [Abstract][Full Text] [Related]
3. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
4. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL
Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
Harrington KJ; Hingorani M; Tanay MA; Hickey J; Bhide SA; Clarke PM; Renouf LC; Thway K; Sibtain A; McNeish IA; Newbold KL; Goldsweig H; Coffin R; Nutting CM
Clin Cancer Res; 2010 Aug; 16(15):4005-15. PubMed ID: 20670951
[TBL] [Abstract][Full Text] [Related]
9. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
10. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
11. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
12. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Groenewegen G; Bloem A; De Gast GC
Cancer Immunol Immunother; 2002 Dec; 51(11-12):630-6. PubMed ID: 12439608
[TBL] [Abstract][Full Text] [Related]
15. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
Kaufman HL; Bines SD
Future Oncol; 2010 Jun; 6(6):941-9. PubMed ID: 20528232
[TBL] [Abstract][Full Text] [Related]
16. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
17. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
[TBL] [Abstract][Full Text] [Related]
19. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
